Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Kellogg to bring back Honey Smacks cereal after Salmonella scare

Kellogg Co. is bringing back Honey Smacks cereal on U.S. retailer shelves in November 2018, months after pulling the product due to a Salmonella scare.

Read More »

Roche lands Tecentriq trial win, still trails Merck in lung cancer

Roche’s Tecentriq plus chemotherapy boosted lung cancer patients’ survival by nearly five months, study data showed, underscoring benefits of the Swiss group’s immunotherapy but still leaving the company trailing a rival’s drug.

Read More »

Roche scores clinical trial win in slowing aggressive type of breast cancer

An immunotherapy cocktail from Roche helped slow an aggressive type of breast cancer where new treatments have proven elusive.

Read More »

Novartis drug cut death risk by 35 percent in gene mutation breast cancer

An experimental cancer drug that Novartis hopes will raise the profile of the company’s oncology portfolio cut the risk of death or disease progression by more than a third in breast cancer patients with a hard-to-target gene mutation.

Read More »

Sanofi’s eczema product Dupixent wins FDA approval to treat asthma

Sanofi SA’s eczema drug Dupixent was approved by the U.S. Food and Drug Administration as an additional maintenance therapy in patients with two types of asthma.

Read More »

Shire’s Takhzyro for rare swelling disorder wins European panel green light

An EMA panel recommended approving a potential blockbuster drug from Shire Plc to treat a rare hereditary disease.

Read More »

Australian watchdog’s appeal against Pfizer ruling dismissed by court

Australia’s competition watchdog said the High Court dismissed its special leave application to appeal a court’s decision on whether Pfizer Inc.’s local unit used the company’s market power to limit competition for the cholesterol-lowering drug Lipitor.

Read More »

FDA snubs Novartis bid to repurpose inflammation drug for heart attacks

The U.S. Food and Drug Administration rejected Novartis’ bid to repurpose canakinumab, a drug already approved for rare inflammatory diseases, for use in a group of heart attack survivors.

Read More »

AbbVie settles Humira biosimilar dispute with Fresenius Kabi

U.S. drugmaker AbbVie Inc. said a patent dispute was settled regarding the Humira biosimilar with Fresenius Kabi Oncology Ltd. and will grant the Germany-based company non-exclusive marketing rights for the drug.

Read More »

Kidney cancer combo meets main study goals

Merck & Co.’s cancer drug Keytruda in combination with Pfizer Inc.’s Inlyta met the main goals of a late-stage study for the most common form of kidney cancer.

Read More »

Novartis pushes deeper into nuclear medicine with $2.1 billion deal

Novartis is acquiring Endocyte and the nuclear medicine specialist’s experimental prostate cancer treatment PSMA-617.

Read More »

Exclusive: Science journal to withdraw chronic fatigue review amid patient activist complaints

A respected science journal is to withdraw a much-cited review of evidence on an illness known as chronic fatigue syndrome amid fierce criticism and pressure from activists and patients.

Read More »

U.S. CDC confirms 62 cases of rare polio-like neurological condition

The U.S. Centers for Disease Control and Prevention confirmed 62 cases of acute flaccid myelitis – a rare, polio-like condition that causes weakness in the arms or legs – across 22 states.

Read More »

Exclusive: Express Scripts covers Amgen, Lilly migraine therapies, excludes Teva drug

Express Scripts Holding – one of the largest U.S. prescription benefits managers – will cover new migraine drugs from Eli Lilly and Amgen, but is excluding a rival medication made by Teva Pharmaceutical Industries after price negotiations with all three manufacturers.

Read More »

Cost of blood pressure drug surges in U.S. after recall

Prices for two dosages of the blood pressure drug valsartan rose more than any other drug in the United States during September 2018, following a recall of much of the drug’s supply.

Read More »

Minnesota accuses insulin makers of deceptive drug pricing

Minnesota’s attorney general filed a lawsuit accusing Sanofi, Novo Nordisk and Eli Lilly of deceptively raising prices for insulin.

Read More »

Restless legs syndrome linked with risk for suicidal thoughts

People with restless legs syndrome may be more likely to think about suicide or to actually make plans to take their own lives, compared to people without the condition, a new study suggests.

Read More »

FDA approves Pfizer’s breast cancer drug Talzenna

The U.S. Food and Drug Administration approved Pfizer Inc.’s Talzenna (talazoparib) for an advanced form of breast cancer.

Read More »

Amgen, Novartis kick off fight for AbbVie blockbuster drug in EU

Rival versions of the world’s top-selling drug – AbbVie’s Humira – went on sale in Europe, years ahead of similar cut-price copies being available in the United States.

Read More »

J&J beats profit estimates, lifts outlook on pharma unit strength

Johnson & Johnson reported slightly better-than-expected third-quarter 2018 profit and raised the company’s full-year forecast.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!

Subscribe

Ad Right Bottom